Abstract: A filament containing a core material (CM) coated with a layer of shell material (SM), wherein the (CM) contains the components a) to c): a) 30 to 80% by volume, based on the total volume of the C) of at least one inorganic powder (IP), b) 20 to 70% by volume, based on the total volume of the CM of at least one binder (B) comprising component b1) b1) at least one polymer (P) and c) optionally at least one additive, wherein the at least one polymer (P) is a polyoxymethylene (POM) homopolymer, a POM copolymer or POM terpolymer and wherein at least some of the OH-end groups of the PO) homopolymer are capped, and the SM contains the components d) to f): d) 75 to 100% by volume, based on the total volume of the SM of at least one thermoplastic polymer, e) optionally at least one inorganic powder (IP), and f) optionally at least one additive, wherein the thickness of the layer of shell material is 0.05 to 0.5 mm.

Abstract: The invention relates to a filament comprising a core material (CM) comprising an inorganic powder (IP) and the core material (CM) is coated with a layer of shell material (SM) comprising a thermoplastic polymer. Further, the invention relates to a process for the preparation of said filament, as well as to three-dimensional objects and a process for the preparation thereof.

Abstract: The present invention is directed to a novel crystalline form of Zolmitriptan, herein designated as Form A, and several novel solvates of Zolmitriptan, herein designated as Form B, C, D, E, F, and G, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.

Abstract: The present invention relates to a process for the production of porous inorganic materials or a matrix material containing nanoparticles with high uniformity of thickness and/or high effective surface area and to the materials obtainable by this process. By the abovementioned process materials with a defined thickness in the region of ±10%, preferably ±5%, of the average thickness are available.

Abstract: A novel crystalline form of Fluvastatin sodium hydrate is described, referred to hereinafter as polymorphic Form G. Furthermore, processes for the preparation of this crystalline form and pharmaceutical compositions comprising this crystalline form are reported.

Abstract: The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. The present invention also is directed to crystalline Form A of Atorvastatin calcium (2:1) that is stable against the formation of the AED impurity. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: The invention relates to a process for preparing solid particles of a phenolic antioxidant from the IRGANOX series in the form of crystals, particularly IRGANOX 1010 and 1098, the crystal particles obtainable by the process, the further processing of the crystal particles, an aqueous dispersion comprising the phenolic antioxidant, novel crystal modifications of pentaerythritol tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate] (?-form) and N,N?-hexane-1,6diyl-bis[3-(3,5-di-tert-butyl-4-hydroxyphenylpropionamide)] (?-form) and aqueous dispersion comprising the new crystal modifications.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hernicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.

Abstract: Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Abstract: An improved process for the preparation of sertraline hydrochloride polymorphic form II is described, which process comprises seeding a solution of sertraline free amine in a ketone with some crystals of polymorphic form II and addition of hydrogen chloride, and wherein the solution is heated before addition of the hydrogen chloride. According to the present process, the metastable form II may be obtained in a reliable way with good yield and high purity with respect to other polymorphic forms as well as preparative residues such as educts or solvents.

Abstract: The present invention is directed to the polymorphic Form B and the amorphous form of Benazepril hydrochloride. The present invention is also directed to processes for the preparation of Form B and the amorphous form of Benazepril hydrochloride, as well as novel processes for the preparation of Form A. Furthermore, the present invention is directed to pharmaceutical compositions comprising these crystalline forms.

Abstract: The invention relates to new reactive diluents of the formulae (Ia, Ib, Ic, Id, Ie) and to an alkyd coating composition comprising them. In a preferred embodiment R1 and R2 are hydrogen; R3 is (meth)acryloyloxy-methyl or phenyl para substituted by vinyl, R4 is phenyl or phenyl para substituted by vinyl or (meth)acryloyloxy; or a substituted phenyl residue of the formula —C6H4CH2—W, wherein W is (meth)acryloyloxy, or an aliphatic residue of the formula —CH2—Y-A, wherein Y is a bond, O—C1-C12alkylene, wherein the alkylene linker is linear or branched and may be interrupted once or more than once by oxygen, A is hydroxy, C1-C6alkoxy, acetoxy, (meth)acryloyloxy, or a phthalate- or maleate-residue; R5 is hydrogen; n is 1; X is —(CH2)—. The invention further relates to a solvent-based or water-based alkyd coating composition comprising 0.3 to 10 wt. % of a mono-, bis- or trisacylphosphinoxide photoinitiator, especially Irgacure 819.

Abstract: An amine ether of formula A wherein a is 1 or 2; and when a is 1, E is E?; when a is 2, E is L; E? is C1-C36 alkyl; C3-C18 alkenyl; C2-C18 alkinyl; C5-C18 cydoalkyl; C5-C18 cycloalkenyl; a radical of a saturated or unsaturated aliphatic bicyclic or tricyclic hydrocarbon of 7 to 12 carbon atoms; C2-C7alkyl or C3-C7alkenyl substituted by halogen; C7-C15 aralkyl or C7-C15 aralkyl substituted by C1-C4 alkyl or phenyl; or E? is a radical of formula (VII) as explained in claim 1; T? is tertiary C4-C18alkyl or phenyl, each of which are unsubstituted or substituted by halogen, OH, COOR21 or C(O)—R22; or T? is C5-C12cycloalkyl; C5-C12 cycloalkyl which is interrupted by at least one O or —NR18—; a polycyclic alkyl radical having 7-18 carbon atoms, or the same radical which is interrupted by at least one O or —NR18—; or T? is —C(G1)(G2)—T?; or C1-C18alkyl or C5-C12cycloalkyl substituted by T? is hydrogen, halogen, NO2, cyano, or is a monovalent organic radical comprising 1-50 carbon atoms; or T? and T? toge

Abstract: A process for the preparation of compounds of formula (I) wherein R1 is unsubstituted or substituted C1-C8alkyl, R2, R3, R4 and R5 are each independently of the others hydrogen, unsubstituted or substituted C1-C8alkyl, C1-C8 alkoxy, phenoxy or benzyloxy, or halogen, Y1 and Y2 are each independently of the other hydrogen or a protecting group, or Y1 and Y2 together form a protecting bridge, and X1 is hydrogen, an organic radical or a cation, in which process a compound of formula (II) wherein R1 R2, R3, R4 and R5 are as defined above and Z1 is a leaving group, is reacted, in the presence of a catalytically effective amount of a palladium catalyst, with a compound of formula (III) wherein R6 is hydrogen, bromine, chlorine, iodine, —OSO2CF3, —COCI, —B(OH)2 or a mono- or di-ester derived from —B(OH)2, Y3 and Y4 are each a protecting group, or Y3 and Y4 together form a protecting bridge, and X1 is as defined above, to form a compound of formula (IV) and if desired the radicals Y3 and Y4 are converted into the radi

Abstract: A process for photocatalytic polymerisation of a cyclic olefin or of at least two different cyclic olefins in the presence of a metal compound as catalyst, which process comprises carrying out a photochemically induced ring-opening metathesis polymerisation in the presence of a catalytic amount of at least one thermostable molybdenum (VI) or tungsten (VI) compound which contains at least two methyl groups or two monosubstituted methyl groups lacking .beta.-hydrogen atoms in the substituent and which are bonded to the metal atom. The process may be carried out by first irradiating and terminating the polymerisation by heating. The process is suitable for fabricating moulded articles, coatings and relief images.